Geron Corp (NASDAQ:GERN)

CAPS Rating: 2 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

GERN News and Commentary

Caps

How do you think GERN will perform against the market?

Add Stock to CAPS Watchlist

All Players

664 Outperform
64 Underperform
 

All-Star Players

85 Outperform
16 Underperform
 

Wall Street

8 Outperform
2 Underperform
 

Top GERN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

jahnjf (63.69)
Submitted April 30, 2018

All clinical trials pointing to approval of game changer drug.

zzlangerhans (99.55)
Submitted August 16, 2013

Geron spiked up a little on rather vague descriptions of progress made in the IST of imetelstat for myelofibrosis but I maintain this one surviving indication for one surviving pipeline candidate doesn't merit an enterprise value of more than 100M.

GERN VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about GERN.

Recs

0
Member Avatar Investochico (< 20) Submitted: 6/14/2018 6:32:37 PM : Outperform Start Price: $3.91 GERN Score: -7.26

Upcoming events should create positive SP move and has good potential for buyout if studies continue to show promise. Company CEO has taken measures to avoid collapse should JNJ walk.

Recs

0
Member Avatar pappyVillagrana (< 20) Submitted: 6/2/2018 12:03:15 PM : Outperform Start Price: $4.02 GERN Score: -10.52

Buyout

Recs

1
Member Avatar jahnjf (63.69) Submitted: 4/30/2018 4:18:16 PM : Outperform Start Price: $3.72 GERN Score: -7.35

All clinical trials pointing to approval of game changer drug.

Leaderboard

Find the members with the highest scoring picks in GERN.

Score Leader

Ravelin

Ravelin (71.79) Score: +412.10

The Score Leader is the player with the highest score across all their picks in GERN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
SheepInvstr213 < 20 3/9/2009 Underperform 5Y $4.59 -21.60% +308.87% +330.47 0 Comment
epc53 27.62 3/3/2009 Underperform NS $3.85 -6.49% +296.72% +303.21 0 Comment
Dudeone 72.63 3/12/2009 Underperform 5Y $4.32 -16.67% +275.69% +292.36 0 Comment
js2776 < 20 1/26/2009 Underperform 3Y $8.15 -55.83% +234.11% +289.94 2 Comments
kevleeyang 44.02 1/23/2009 Underperform NS $7.23 -50.21% +237.30% +287.50 0 Comment
yourfavoritepers 79.08 1/26/2009 Underperform 3W $7.47 -51.81% +234.47% +286.28 0 Comment
Lafleur526 30.93 1/26/2009 Underperform 3W $7.47 -51.81% +234.47% +286.28 0 Comment
dcfoolz 70.34 1/26/2009 Underperform 5Y $7.47 -51.81% +234.47% +286.28 0 Comment
SheepInvstr321 94.48 1/23/2009 Underperform 5Y $7.36 -51.08% +233.91% +285.00 0 Comment
e2003 95.42 3/30/2009 Underperform 1Y $4.75 -24.21% +248.17% +272.38 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPiperJaff 87.40 8/12/2013 Outperform NS $1.59 +126.42% +63.09% +63.33 0 Comment
TrackPiperJaff 87.40 1/18/2013 Outperform NS $1.78 -30.90% +5.76% -36.66 3/14/2013 @ $1.23 0 Comment
TrackPoisedTo < 20 8/31/2012 Underperform 5Y $2.64 +36.36% +94.45% +58.09 0 Comment
TrackStifel 93.94 8/30/2012 Outperform NS $2.57 +40.08% +94.99% -54.91 0 Comment
trackwbbsecuriti 20.08 11/16/2011 Outperform NS $1.68 +114.29% +120.13% -5.84 0 Comment
TrackRodmanRen < 20 1/23/2009 Outperform NS $7.04 -48.86% +243.89% -292.76 0 Comment
trackmerriman 69.15 12/11/2008 Outperform NS $4.29 -16.08% +211.51% -227.60 0 Comment
TrackUBS 92.06 1/29/2008 Outperform NS $5.00 -28.00% +110.38% -138.38 0 Comment
TrackEveillard 95.60 9/30/2007 Outperform NS $7.32 -50.82% +88.66% -139.48 2 Comments
TrackTobinSmith < 20 11/11/2006 Outperform 1Y $8.59 -58.09% +110.95% -169.04 0 Comment
TrackJimCramer 85.44 3/24/2006 Underperform 3W $8.33 -56.78% +126.10% +182.88 0 Comment

Featured Broker Partners


Advertisement